Answer
With glofitamab (Columvi) monotherapy, neutropenia (including decreased neutrophil count) occurred in 40.0% of patients, severe neutropenia (Grade 3 or 4) in 29.0%, prolonged neutropenia (lasting longer than 30 days) in 11.7%, and febrile neutropenia in 3.4%.
Sources for this answer
- Columvi 2.5 mg, 10 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.8 Undesirable effects · Version 6Document updated
Sources checked